Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 25, 2022
Share
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 2,487.21 million compared to CNY 676.96 million a year ago. Revenue was CNY 2,487.21 million compared to CNY 676.96 million a year ago. Net income was CNY 1,389.04 million compared to CNY 341.25 million a year ago. Basic earnings per share from continuing operations was CNY 9.0671 compared to CNY 2.3758 a year ago. Diluted earnings per share from continuing operations was CNY 9.0067 compared to CNY 2.3758 a year ago.
Wuhan Easy Diagnosis Biomedicine Co., Ltd. is a China-based company which is mainly engaged in research and development, manufacture and sales of Point of Care Testing (POCT) rapid diagnostic reagents and quick testing instruments. The Company's main products are POCT rapid diagnostic reagents, which can be divided into six categories: infectious diseases, cardiovascular and cerebrovascular diseases, kidney diseases, diabetes, gynecology and eugenics, and health checkups. The Company's main products are mainly used in domestic hospitals, health service centers, community clinics, medical examination centers and other medical institutions.
WUHAN EASY DIAGNOSIS BIOMEDICINE CO.,LTD. 
